Adalimumab maintains remission of Crohn's disease after up to 4 years of treatment: data from CHARM and ADHERE

BACKGROUND: Therapies that maintain remission for patients with Crohn's disease are essential. Stable remission rates have been demonstrated for up to 2 years in adalimumab-treated patients with moderately to severely active Crohn's disease enrolled in the CHARM and ADHERE clinical trials....

Cur síos iomlán

Na minha lista:
Sonraí Bibleagrafaíochta
Foilsithe in:Aliment Pharmacol Ther
Main Authors: Panaccione, R, Colombel, J-F, Sandborn, W J, D'Haens, G, Zhou, Q, Pollack, P F, Thakkar, R B, Robinson, A M
Formáid: Artigo
Teanga:Inglês
Foilsithe: Blackwell Publishing Ltd 2013
Ábhair:
Inflammatory Bowel Disease
Rochtain Ar Líne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4670480/
https://ncbi.nlm.nih.gov/pubmed/24134498
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/apt.12499
Clibeanna: Cuir Clib Leis
Gan Chlibeanna, Bí ar an gcéad duine leis an taifead seo a chlibeáil!

Míreanna Comhchosúla